A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
- 14 August 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 57 (3), 489-495
- https://doi.org/10.1212/wnl.57.3.489
Abstract
Objective: To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD. Methods: Patients (n = 286; mean age, 72.5 years) with possible or probable AD from five Northern European countries were randomized to receive either donepezil (n = 142; 5 mg/day for 28 days, followed by 10 mg/day) or placebo (n = 144) for 1 year. Results: The study was completed by 66.9% of the donepezil- and 67.4% of the placebo-treated patients. The benefit of donepezil over placebo was demonstrated by the Gottfries-Bråne-Steen (a global assessment for rating dementia symptoms) total score at weeks 24, 36, and 52 (p < 0.05) and at the study end point (week 52, last observation carried forward; p = 0.054). Advantages of donepezil over placebo were also observed in cognition and activities of daily living (ADL) assessed by the Mini-Mental State Examination at weeks 24, 36, and 52, and the end point (p < 0.02) and by the Progressive Deterioration Scale at week 52 and the end point (p < 0.05). Adverse events (AE) were recorded for 81.7% of donepezil- and 75.7% of placebo-treated patients, with 7% of donepezil- and 6.3% of placebo-treated patients discontinuing because of AE. Treatment response to donepezil was not predicted by APOE genotype or sex in this population. Conclusion: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.Keywords
This publication has 26 references indexed in Scilit:
- The Gottfries-Bråne-Steen Scale: Validity, Reliability and Application in Anti-Dementia Drug TrialsDementia and Geriatric Cognitive Disorders, 2000
- Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography studyAnnals of Neurology, 2000
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- The Neuropsychiatric InventoryNeurology, 1994
- Cognitive Decline in Alzheimer's Disease: Elaborating on the Nature of the Longitudinal Factor Structure of the Mini-Mental State ExaminationInternational Psychogeriatrics, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- A new rating scale for dementia syndromesArchives of Gerontology and Geriatrics, 1982
- Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.BMJ, 1978
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975